Catalyst Pharmaceuticals (CPRX) Q3 2024 earnings summary

Executive summary

• Achieved Q3 2024 total revenues of $128.7 million, up 25.3% year-over-year, driven by strong Firdapse, Agamree, and Fycompa performance.

• Expanded product portfolio and global reach, including Agamree launch and Firdapse approval in Japan, with launch expected by end of Q4 2024.

• Maintained robust liquidity with $442.3 million in cash and cash equivalents at quarter-end, supporting strategic initiatives and future growth.

• Settled key patent litigation, strengthening intellectual property protection for Firdapse and Fycompa.

• Focused on business development, potential acquisitions, and global expansion in LATAM, APAC, and Canada.

Financial highlights

• Q3 2024 total revenues: $128.7 million (+25.3% YoY); net product revenues: $126.4 million (+23.2% YoY).

• Firdapse Q3 net sales: $79.3 million (+19.7% YoY); Agamree Q3 net sales: $15 million; Fycompa Q3 net sales: $32.1 million (-11.9% YoY).

• GAAP net income: $43.9 million ($0.35/diluted share) vs. net loss of $38.8 million in Q3 2023.

• Operating income for Q3 2024 was $50.9 million, reversing a $37.2 million loss in Q3 2023.

• Cost of sales: $19.3 million (up from $14.2 million YoY), mainly due to increased royalties as Firdapse sales surpassed $100 million.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $475–$485 million.

• Firdapse full-year net revenue guidance narrowed to $300–$310 million.

• Agamree full-year net revenue guidance raised to $40–$45 million; Fycompa full-year net revenue guidance reaffirmed at $130–$135 million.

• Full-year 2024 R&D expense expected to be less than $15 million.

• Sufficient cash to fund operations for at least 12 months; ongoing focus on expanding product portfolio and global footprint.